» Articles » PMID: 22445296

Clinical Outcome for Nasopharyngeal Carcinoma with Predominantly WHO II Histology Treated with Intensity-modulated Radiation Therapy in Non-endemic Region of China

Overview
Journal Oral Oncol
Publisher Elsevier
Specialty Dentistry
Date 2012 Mar 27
PMID 22445296
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To evaluate the clinical outcomes of using intensity-modulated radiotherapy (IMRT) in the primary treatment of nasopharyngeal carcinoma (NPC) in Northwest China, including assessments of failure patterns, toxicities and potential prognostic factors.

Methods And Materials: Between January 2006 and June 2010, 193 newly diagnosed non-metastatic NPCs were treated by IMRT with simultaneous-integrated boost (SIB) technique in Xijing Hospital of Northwest China. Cisplatin-based chemotherapy was offered to 85.5% patients. Acute and late toxicities were graded according to the Radiation Therapy Oncology Group (RTOG) scoring criteria. Prognostic factors were assessed by univariate or multivariate analysis. Statistical analyses were performed on survival and failure patterns.

Results: Median follow-up was 34 months. WHO type II was the predominant histology for NPCs (69.9%) in our study group. Twelve patients experienced local regional failure and total distant metastasis occurred in 34 patients, representing the major mode of failure. The 3-year local recurrence-free (LRFS), regional recurrence-free (RRFS), distant metastasis-free (DMFS) and overall survival (OS) rates were 86.6%, 86.7%, 86.4%, and 85.7%, respectively. Multivariate analyses showed N-classification, age (≤ 50 vs. >50) and WHO type (WHO II vs. WHO III) were independent predictors for DMFS, LRFS and OS. Tumor volume (≤ 50 cm(3) vs. >50 cm(3)) and presence of anemia were independent significant prognostic factors for profession-free survival (PFS). No significant difference was observed between different T categories. Acute and late toxicities were mild or moderate. No grade IV toxicities were observed.

Conclusions: WHO II was the predominant histology and a significant poor prognostic factor in our study group, indicating different carcinogenetic pathways of NPC between endemic and non-endemic regions. Our experience of using IMRT in the treatment of NPC in non-endemic region showed excellent locoregional control and favorable toxicity profiles.

Citing Articles

Gemcitabine and cisplatin induction chemotherapy followed by concurrent chemoradiotherapy for stage III-IVA nasopharyngeal carcinoma: A real-world study.

Van D, Viet S, Phu G Sci Prog. 2025; 108(1):368504241312582.

PMID: 39885780 PMC: 11783467. DOI: 10.1177/00368504241312582.


Survival rate prediction of nasopharyngeal carcinoma patients based on MRI and gene expression using a deep neural network.

Zhang Q, Wu G, Yang Q, Dai G, Li T, Chen P Cancer Sci. 2022; 114(4):1596-1605.

PMID: 36541519 PMC: 10067413. DOI: 10.1111/cas.15704.


Current Radiotherapy Considerations for Nasopharyngeal Carcinoma.

Ng W, Chow J, Beitler J, Corry J, Mendenhall W, Lee A Cancers (Basel). 2022; 14(23).

PMID: 36497254 PMC: 9736118. DOI: 10.3390/cancers14235773.


A dynamic nomogram combining tumor stage and magnetic resonance imaging features to predict the response to induction chemotherapy in locally advanced nasopharyngeal carcinoma.

Jiang Y, Liang Z, Chen K, Li Y, Yang J, Qu S Eur Radiol. 2022; 33(3):2171-2184.

PMID: 36355201 DOI: 10.1007/s00330-022-09201-8.


Prognostic models for early and late tumor progression prediction in nasopharyngeal carcinoma: An analysis of 8292 endemic cases.

Zhang L, Zheng W, Zhu W, Deng Q, Peng J, Li Y Cancer Med. 2022; 12(5):5384-5396.

PMID: 36301691 PMC: 10028159. DOI: 10.1002/cam4.5361.